5 Key Takeaways

• 1

  Corneal neovascularization (CNV) poses significant challenges, leading to inflammation, scarring, and vision loss.

• 2

  A new study presents non-invasive antibody eye drops that can penetrate ocular barriers and suppress pathologic angiogenesis.

• 3

  The topical therapy utilizes a small anti-VEGF antibody, sdVE01, which is three times smaller than ranibizumab but retains similar efficacy.

• 4

  Dithiolane molecule-based nanoformulations enhance the delivery of the antibody, allowing for deeper penetration into ocular tissues.

• 5

  This approach could provide a non-invasive alternative to intraocular injections, improving patient compliance and reducing procedural risks.